單一藥物之早期臨床試驗設計

以作者查詢圖書館館藏

、以作者查詢臺灣博碩士

、以作者查詢全國書目

、勘誤回報

、線上人數：22

、訪客IP：3.17.150.163

姓名

龔宸瀧(KUNG, CHEN-LUNG) 查詢紙本館藏

畢業系所

統計研究所

論文名稱

單一藥物之早期臨床試驗設計
(Early clinical trial designs for single drug)

相關論文

★ 藥物最低有效劑量之無母數鑑別	★ 根據貝氏檢定建構的第一期臨床試驗設計
★ 第一期臨床試驗之貝氏調適設計	★ 強餘震之即時貝氏預測
★ 鑑別最佳添加藥物劑量的兩階段早期臨床試驗設計	★ 臺灣地區地下水品質之統計研究
★ 右設限存活資料之下每日可服劑量之研究	★ 集集餘震之統計研究
★ 多群資料下最低有效劑量之聯合鑑別	★ 最大餘震規模之統計分析
★ 最大餘震發生時間之統計分析	★ 地震預測之統計分析
★ 加權Kaplan-Meier統計量之推廣	★ 鑑別藥物最低有效劑量之檢定
★ 餘震序列RJ模型之貝氏分析	★ 藥物最低有效劑量之穩健鑑別

檔案

[Endnote RIS 格式]

[Bibtex 格式]

[相關文章]

[文章引用]

[完整記錄]

[館藏目錄]

至系統瀏覽論文 (2024-8-1以後開放)

摘要(中)

針對癌症的化療藥之研發，傳統的第一期臨床試驗主要是找尋該藥物的最大耐受劑量，而後循序進入第二期臨床試驗探索短期藥效。近年發展的標靶藥之毒性一般較傳統化療藥物低且藥效較佳，但是其藥效機率可能隨著劑量的增高呈現高原期或是先升後降的型態，因此標靶藥之早期臨床試驗的重點為尋找最佳生物劑量，亦即服用該劑量的病患具有最佳藥效且發生劑量限制毒性的機率低於設定的目標毒性機率。本文針對二元的藥效與毒性反應，建立一種早期臨床試驗設計，其中藉比較毒性機率的可信上下界與目標毒性機率，同時比較藥效機率的貝氏估計與期望的藥效機率，建立劑量升降過程，所以此一設計記作 CLUB12。最後在優化風險收益權衡之下，估計最佳藥效生物劑量。此設計並無假設任何特定的模式描述劑量毒性或劑量藥效關係，故CLUB12 為一模型輔助設計。本文最後進行廣泛的模擬研究，利用多種效能指標探討CLUB12 在各種情境下的表現，並與其他早期臨床試驗設計比較。模擬結果顯示本文提出的CLUB12設計在正確估計最佳生物劑量與合理的配置劑量方面較具有競爭力。

摘要(英)

In the development of chemotherapy for cancer treatment, the traditional phase I clinical trial is mainly to find the maximum tolerated dose of the drug under study, and then the short-term efficacy is explored in the phase II clinical trial. The molecular targeted agent (MTA) recently developed for cancer treatment generally produces lower toxicity than does the chemotherapy drugs and gives better efficacy. However, the efficacy probability of the MTA may have a plateau or up-and-down pattern after a high dose. Therefore, the purpose of an early clinical trial for the MTA is to find the optimal biological dose (OBD) so that patients taking the dose have the best efficacy yet maintain the target toxicity probability (TTP). This paper proposes an early clinical trial design for MTAs based on binary toxicity and efficacy responses. The dose escalation/de-escalation procedure is constructed by comparing the credible upper and lower bounds of the toxicity probability with the TTP and the Bayesian estimate of the efficacy probability with the expected one. Hence the proposed design is denoted by CLUB12. The OBD is finally estimated as the one that optimizes the risk-benefit trade-off. The CLUB12 design is a model-assisted design since it does not assume any specific model for the dose-toxicity or dose-efficacy relationship. An extensive simulation study is further implemented to investigate the design efficiency of the CLUB12 design relative to other designs. The simulation results show that the CLUB12 design is relatively competitive in correctly selecting the OBD and reasonably assigning dose in the trial.

關鍵字(中)

★ 早期臨床試驗設計
★ 最佳生物劑
★ 貝氏方法
★ 可信區間
★ 模型輔助設計

關鍵字(英)

★ Early clinical trial design
★ optimal biological dose
★ Bayesian method
★ credible interval
★ model-assistant design

論文目次

摘要 I
Abstract II
致謝辭 IV
目錄 V
圖目錄 VII
表目錄 XII
第一章研究動機與目的 1
第二章文獻回顧 5
2.1 第一期臨床試驗設計 5
2.2 早期臨床試驗設計 7
第三章早期臨床試驗設計 13
3.1 毒性機率及藥效機率的貝氏分析 13
3.2 劑量升降規則 14
第四章模擬研究 18
4.1模擬研究設計 18
4.2 模擬研究結果 19
4.2.1 CLUB12設計參數選取 19
4.2.2 CLUB12與STEIN設計效能的比較 20
第五章結論與未來研究 22
參考文獻 24
附錄 27

參考文獻

Guo, W., Wang, S.J., Yang, S., Lynn, H. & Ji, Y. (2017) A Bayesian interval dose-finding design addressing Ockham’s razor: MTPI-2. Contemporary Clinical Trials; 58:23-33.
Hoering, A., Mitchell, A., LeBlanc, M. & Crowley, J. (2013) Early phase trial design for assessing several dose levels for toxicity and efficacy for targeted agents. Clinical Trials; 10:422-429.
Ji, Y., Li, Y. & Bekele, N. (2007) Dose-finding in phase I clinical trials based on toxicity probability intervals. Clinical Trials; 4:235-244.
Ji, Y., Liu, P., Li, Y. & Bekele, N. (2010). A modified toxicity probability interval method for dose-finding trials. Clinical Trials; 7:653-663.
Jaki T, Clive S, Weir CJ. (2013) Principles of dose finding studies in cancer: a comparison of trial designs. Cancer Chemother Pharmacol; 71:1107-14.
Liu, S. & Yuan, Y. (2015) Bayesian optimal interval designs for phase I clinical trials. Journal of the Royal Statistical Society: Series C Applied Statistics; 64:507-523.
Li DH, Whitmore JB, Guo W, et al (2017) Toxicity and efficacy probability interval design for phase I adoptive cell therapy dose-finding clinical trials. Clin Cancer Res; 23:13-20
Lin, R. & Yin, G. (2017) STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials. Statistics in medicine; 36:4106-4120.
Lin, R., Zhou, Y., Yan, F., Li, D. & Yuan, Y. (2020) BOIN12:Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies. JCO Precis Oncol; 4:1393-1402
O′Quigley, J., Pepe, M. & Fisher, L. (1990) Continual reassessment method: A practical design for phase I clinical trials in cancer. Biometrics; 46:33-48.
Riviere, M.K., Yuan, Y., Jourdan, J.H., Dubois, F. & Zohar, S. (2017) Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization. Statistics in Medicine; 27:466-479.
Storer, B.E. (1989) Design and analysis of phase I clinical trials. Biometrics; 45:925-937.
Sachs JR, Mayawala K, Gadamsetty S, et al (2016) Optimal dosing for targeted therapies in oncology: Drug development cases leading by example.Clin Cancer Res; 22:1318-1324.
Thall PF, Cook JD (2004) Dose-finding based on efficacy-toxicity trade-offs. Biometrics; 60:684-693
Yan, F., Mandrekar, S.J. & Yuan, Y. (2017) Keyboard: A novel bayesian toxicity probability interval design for phase I clinical trials. Clinical Cancer Research; 23:3994-4003.
Zhou, H., Murray, T.A., Pan, H. & Yuan, Y. (2016) Comparative review of novel model‐assisted designs for phase I clinical trials. Statistics in Medicine; 37:2208-2222.
Zhou, Y., MS, Lee, J. & Yuan, Y. (2019) A Utility-based Bayesian Optimal Interval (U-BOIN) Phase I/II Design to Identify the Optimal Biological Dose for Targeted and Immune Therapies. Stat Med.; 5299-5316
Zang, Y., Lee, J.J. & Yuan, Y. (2014) Adaptive designs for identifying optimal biological dose for molecularly targeted agents. Clinical Trials; 11:319-327.

指導教授

陳玉英

審核日期

2022-8-3

推文